Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization
The success of in vitro fertilization is based mainly on uterine implantation embryo. An excessive uterine contractility may interfere with implantation by a movement of the embryo in the uterus. The inhibition of the uterine contractility may have a positive effect on success rate of in vitro fertilization. It is through parenteral injection of glucagon and its spasmolytic effect on various smooth muscles and thereby on the uterine muscle, at the time of embryo transfer, the investigators intend to improve the pregnancy rates obtained after IVF.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
|Official Title:||Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization|
- Uterine muscle relaxation [ Time Frame: 30 minutes ] [ Designated as safety issue: No ]Determine if the intramuscular administration of 1mg of Glucagon 10 minutes before the embryo transfer is associated with a uterine muscle relaxation.
- Embryo implantation and pregnancy rate [ Time Frame: 7 weeks ] [ Designated as safety issue: No ]Determine if the intramuscular administration of 1mg of Glucagon 10 minutes before the embryo transfer is associated with higher implantation and pregnancy rates than during embryo transfer without glucagon.
|Study Start Date:||October 2013|
|Estimated Study Completion Date:||February 2015|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of Glucagon.
The second recording is doing the same way 10 minutes after the Glucagon injection, just before the embryo transfer.
Placebo Comparator: Sodium chloride 0.9%
The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of the placebo.
The second recording is doing the same way 10 minutes after the placebo injection, just before the embryo transfer.
Women will have a cycle of in vitro fertilization (IVF) and follow the standard protocol established by the clinic ovo or the fertility clinic of CHUM. On the day of embryo transfer, the investigators will administer 1 mg of Glucagon or placebo intramuscularly 10 minutes before the embryo transfer. The uterine contractility will be measured by ultrasound before and after injection to document the impact of Glucagon on it and we will proceed to embryo transfer.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01674283
|Contact: Kécelle Viaud, RN||(514) 798-2000 ext email@example.com|
|Contact: Sophie Leblanc, RN||514-798-2000 ext firstname.lastname@example.org|
|Clinique Ovo||Not yet recruiting|
|Montréal, Quebec, Canada, H4P 2S4|
|Contact: Shirley Brugerie, Director|
|Contact: Kécelle Viaud, RN 514-798-2000 ext 759 email@example.com|
|Principal Investigator: Himaya Eric, MD|
|Principal Investigator:||Eric Himaya, Dr||clinique ovo and CHUM|